Extended-release pregabalin for nerve pain from diabetes or shingles
Compares extended-release pregabalin with standard pregabalin for nerve pain in adults.
Key facts
- Who runs it
- Brainfarma Industria Química e Farmacêutica S/A
- Where
- Brazil15 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Extended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 348 people, planned
- Started
- 18 Jun 2026
- Expected to end
- 1 Jun 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Experimental: Pregabalin XR
- Comparator: Dorene Tabs
- Comparator placebo
- experimental placebo
- Record updated
- 20 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with nerve pain caused by diabetes or by shingles (postherpetic neuralgia). It compares extended-release and immediate-release pregabalin tablets.
- Age
- 18 to 75 years
- Sex
- All sexes
- Disease stage
- Nerve pain from type 1 or 2 diabetes, with symptoms for at least 6 months, or nerve pain for at least 3 months after a shingles rash. Pain must be at least 4 on a 0 to 10 scale.
- Earlier treatment
- People with diabetes must take diabetes medicine at a stable dose for at least 30 days. No nerve surgery for the neuropathy. No nerve blocks or nerve pain medicines (such as opioids, gabapentin, antidepressants, antiepileptic drugs) in the past 7 days. Pregabalin or gabapentin must not have failed before.
- Biomarker or test result
- For diabetes: HbA1c ≤ 11% (97 mmol/mol).
Main reasons for not taking part
- Other pain, or skin problems in the painful area, that could affect the assessment
- Allergy to pregabalin or gabapentin
- Cancer in the past 2 years (except basal cell carcinoma), nerve disease, unstable heart disease, mental illness, or hepatitis B, hepatitis C or HIV
- Kidney function (glomerular filtration rate) < 60 mL/min/1.73 m², or AST/ALT 2.5 times above the upper limit
- Pregnancy, breastfeeding, or plans to become pregnant; drug or alcohol abuse in the past 2 years
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- The following criteria must be met for a participant to be included in the study:
- Participants of either sex, aged 18 to 75 years
- Be able to understand and agree to participate in the study, undergo the procedures, and attend the visits, as indicated by signing the informed consent form approved by the CEP/Conep System
- Have a diagnosis of peripheral neuropathic pain associated with:; diabetes mellitus (type 1 or 2), with glycated hemoglobin (HbA1c) levels ≤ 11%, documented symptoms of peripheral diabetic neuropathy for at least 6 months, and use of medication for glycemic control at a stable dose for at least 30 days; postherpetic neuralgia, with pain symptoms for at least 3 months following a skin rash due to an acute episode of herpes zoster
- Presence of neuropathic pain, with an intensity of ≥ 4 on the 11-point DPRS numerical scale (from 0 "no pain" to 10 "worst possible pain"‡). ‡ Pain intensity ≥ 4 will be confirmed at the initial visit (IV); during the screening/randomization visit, Participant Diary No. 1 containing the DPRS scales will be provided, in which the participant will record pain intensity daily upon waking and at the end of the day for 7 days (±2 days). The mean value for pain intensity recorded during the Screening/Randomization Phase will be used to confirm eligibility at the initial visit (IV)
- Participants who are unable to become pregnant (postmenopausal women, defined as 12 months or more of amenorrhea, or who have undergone surgical sterilization*; and men who have undergone vasectomy**) OR participants of reproductive potential who agree to use a reliable method of contraception***; Female sterilization (undergoing bilateral surgical oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least 6 weeks prior to administration of the investigational drug; Male sterilization at least 6 months prior to screening. *** If the participant is of childbearing age and decides to participate in the study, they must use or request that their partner use a safe contraceptive method. A safe contraceptive method is defined as the use of at least one of the following: condoms, a diaphragm, and/or a hormonal method (estrogenic and/or progestogenic) in the form of medication, including oral, vaginal, injectable, transdermal, and intrauterine devices. Only participants who expressly declare themselves exempt from the risk of pregnancy-whether because they do not engage in sexual activity or because they engage in it in a non-reproductive manner-will have the right to participate in the study without the mandatory use of contraceptives. Examples include participants who have undergone a vasectomy, those with an infertile partner, or those practicing total heterosexual abstinence; The decision regarding the best contraceptive method to use will be made jointly by the physician and the study participant. If there are any costs involved, the chosen contraceptive method will be provided by the sponsor free of charge for as long as necessary. In addition, condoms with spermicide will be provided to participants at all study visits, when applicable
Who cannot take part
- Having undergone neurosurgical therapy for the treatment of neuropathy
- Current use, or use within the past 7 days, of nerve block therapy and/or medications commonly used to treat neuropathic pain (e.g., benzodiazepines, skeletal muscle relaxants, capsaicin, local anesthetics, opioids, memantine), antiepileptic drugs (e.g., carbamazepine, clonazepam, phenytoin, valproic acid, lamotrigine, topiramate, gabapentin), antidepressants (e.g., tricyclics, serotonin reuptake inhibitors, venlafaxine), and potential neurotoxins (e.g., hydroxychloroquine, deferoxamine, thioridazine, vigabatrin)
- Any skin condition that potentially alters sensation in the affected dermatome or area of neuropathic involvement, which could interfere with the assessment
- History of treatment failure or hypersensitivity to pregabalin or gabapentin
- History of neoplastic disease within the past 2 years (excluding basal cell carcinoma), neurological disease, unstable heart disease, psychiatric conditions (particularly suicidal ideation), and/or infection with hepatitis B, hepatitis C, or HIV
- History of illicit drug abuse in the past 2 years
- History of alcoholism (average alcohol intake exceeding 3 standard drinks* per day or more than 7 standard drinks per week for women, and exceeding 4 standard drinks per day or more than 14 standard drinks per week for men) in the past 2 years; A standard drink is: a can of regular beer (330 mL at 4%); a shot of distilled spirits (30 mL at 40%); a glass of wine or a small glass of sherry (100 mL at 12% or 70 mL at 18%); a small glass of liqueur or similar (50 mL at 25%) (53)
- Having any condition that prevents participation, at the investigator's discretion
- Current laboratory abnormalities in liver enzymes (elevated AST and/or ALT 2.5 times the upper limit of the reference range) and/or renal insufficiency (glomerular filtration rate < 60 mL/min/1.73 m²)
- A positive response to any of the following criteria will exclude the participant from the study:
- The presence of pain unrelated to the primary diagnosis of diabetic peripheral neuropathy or postherpetic neuralgia that could interfere with the evaluation
- Being pregnant, breastfeeding, or intending to become pregnant during the study period
- Having participated in clinical studies in the past 12 (twelve) months, unless there may be a direct benefit to the study participant, at the investigator's discretion
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial is currently available in Brazil.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Extended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia
The 2 groups in the trial
- Pregabalin XR: Extended-release pregabalinTreatment being tested
Pregabalin XR: will receive extended-release pregabalin tablets at an initial dose of 82.5 mg once daily (during the first week for titration). The dose may be adjusted every 7 days during the first 4 weeks of treatment, up to a maximum of 660 mg once daily. In addition, the experimental group may receive a placebo twice daily.
Treatment: Experimental: Pregabalin XR and experimental placebo
- Dorene Tabs: Immediate-release pregabalinExisting treatment, for comparison
Dorene Tabs: will receive immediate-release pregabalin tablets (Dorene Tabs) at a starting dose of 75 mg twice daily. The dose may be adjusted every 7 days during the first 4 weeks of treatment, up to a maximum of 300 mg twice daily. In addition, the comparison group will receive a placebo once daily.
Treatment: Comparator: Dorene Tabs and Comparator placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase III, Multicenter, Randomized, Double-blind, Double-dummy, Controlled, Parallel-group, Non-inferiority Clinical Trial to Evaluate the Efficacy and Safety of Extended-release Pregabalin Tablets Compared With Immediate-release Pregabalin Tablets, in the Relief of Neuropathic Pain in Participants With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia.
- Plain-language title
- Extended-release pregabalin for nerve pain from diabetes or shinglesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07712913, who can take part
- Record updated
- 20 July 2026